ArticleBreast cancer : basic and clinical research2019
The Chemokine Receptor CXCR3 Isoform B Drives Breast Cancer Stem Cells.
Article in Breast cancer : basic and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Drug repositioning for immunotherapy in breast cancer using single-cell analysis.NPJ systems biology and applications · 2024Pooled it
- S1PR4 connects cancer pain to pan-cancer mechanisms and reveals prognosis, immune infiltration and therapeutic potential.Discover oncology · 2026Article
- The metastatic role of the CXCL10-CXCR3 axis and its therapeutic potential in osteosarcoma.Journal of bone oncology · 2025Article
- Non-immune targeting of CXCR3 compromises mitochondrial function and suppresses tumor growth in glioblastoma.Cell death discovery · 2025Article
- CXCR3 inhibitors for therapeutic interventions: current status and perspectives.Frontiers in pharmacology · 2025Review
- Two transcriptionally and functionally distinct waves of neutrophils during mouse acute liver injury.Hepatology communications · 2024Article
- The application of nanoparticles in theranostic systems targeting breast cancer stem cells: current progress and future challenges.Stem cell research & therapy · 2023Review
- The role of CXCR3 and its ligands in cancer.Frontiers in oncology · 2022Review
- Regulation of Tumor and Metastasis Initiation by Chemokine Receptors.Journal of Cancer · 2022Review
- Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies.Biochimica et biophysica acta. Reviews on cancer · 2021Review
- Interleukin-30 feeds breast cancer stem cells via CXCL10 and IL23 autocrine loops and shapes immune contexture and host outcome.Journal for immunotherapy of cancer · 2021Article
- Chemokine signaling in cancer-stroma communications.Journal of cell communication and signaling · 2021Review
- Modulation of the chemokine/chemokine receptor axis as a novel approach for glioma therapy.Pharmacology & therapeutics · 2021Review
- Chemokines orchestrate tumor cells and the microenvironment to achieve metastatic heterogeneity.Cancer metastasis reviews · 2021Review
- Claudin-Low Breast Cancer Inflammatory Signatures Support Polarization of M1-Like Macrophages with Protumoral Activity.Cancers · 2021Article
- miR-1298-5p Influences the Malignancy Phenotypes of Breast Cancer Cells by InhibitingCancer management and research · 2021Article
- Eight immune-related genes predict survival outcomes and immune characteristics in breast cancer.Aging · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We are seeking to identify molecular targets that are relevant to breast cancer cells with stem-like properties. There is growing evidence that cancer stem cells (CSCs) are supported by inflammatory mediators expressed in the tumor microenvironment. The chemokine receptor CXCR3 binds the interferon-γ-inducible, ELR-negative CXC chemokines CXCL9, CXCL10, and CXCL11 and malignant cells have co-opted this receptor to promote tumor cell migration and invasion. There are 2 major isoforms of CXCR3: CXCR3A and CXCR3B. The latter is generated from alternative splicing and results in a protein with a longer N-terminal domain. CXCR3 isoform A is generally considered to play a major role in tumor metastasis. When the entire tumor cell population is examined, CXCR3 isoform B is usually detected at much lower levels than CXCR3A and for this, and other reasons, was not considered to drive tumor progression. We have shown that CXCR3B is significantly upregulated in the subpopulation of breast CSCs in comparison with the bulk tumor cell population in 3 independent breast cancer cell lines (MDA-MB-231, SUM159, and T47D). Modulation of CXCR3B levels by knock in strategies increases CSC populations identified by aldehyde dehydrogenase activity or CD44
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.